Research progress of antineoplastic drugs targeting platelets
- Author:
Yue-Ke ZHOU
1
;
Cheng QIAN
1
;
Yu TANG
1
;
Zhong-Hong WEI
1
;
Yin LU
1
;
Ai-Yun WANG
1
;
Yin LU
2
;
Ai-Yun WANG
2
Author Information
- Publication Type:Journal Article
- Keywords: antitumor drugs; platelet activation; platelet receptor; platelet-tumor cell interaction; tumor; tumorigenesis and metastasis
- From: Chinese Pharmacological Bulletin 2024;40(1):20-25
- CountryChina
- Language:Chinese
- Abstract: Platelets have long been recognized as key players in hemostasis and thrombosis; however, there is growing evidence that they are also involved in cancer. Preclinical and clinical studies have shown that platelets can promote tumorigenesis and metastasis through various crosstalks between platelets and cancer cells. Platelets play an active role in all stages of tumorigenesis, including tumor growth, tumor cell extravasation, and metastasis. In addition, thrombocytosis in cancer patients is associated with poor patient survival. Platelets are also well-placed to coordinate local and distant tumor-host interactions due to the a- bundance of microparticles and exosomes. Therefore, antitumor drugs targeting platelets have great development and application prospects. The following will review the research progress of anti-tumor drugs targeting platelets.
